Journals / Marmara Pharmaceutical Journal / 2017 / Cilt: 21 - Sayı: 3

Investigation of fragment based quantitative regression on a series of substituted chromen-2-one derivatives as FXa inhibitors

Pages
620–630
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results of GQSAR models may lead to better understanding of design and development of novel FXa inhibitors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Factor Xa (FXa), a trypsin-like serine protease, is well- established target for the development of the anticoagulants.
📊
Key Findings & Data:In this present communication, we report development and validation of the group based quantitative structure activity relationship (GQSAR) studies on 48 chromen-2-one derivatives as effective inhibitors of FXa.
💡
Conclusion & Impact:The results of GQSAR models may lead to better understanding of design and development of novel FXa inhibitors.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Factor Xa (FXa), a trypsin-like serine protease, is well- established target for the development of the anticoagulants. Number of molecules were reported as Factor Xa inhibitors but most of them have pharmacokinetic issues. In this present communication, we report development and validation of the group based quantitative structure activity relationship (GQSAR) studies on 48 chromen-2-one derivatives as effective inhibitors of FXa. All the molecules were fragmented into eleven functional fragments (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11). All the developed GQSAR models were generated using multiple linear regression analysis (MLR). The generated GQSAR models were selected on the basis of statistical data that models having r 2 should be above 0.6 were used to check the external predictivity while the significance of the model was decided on the basis of F value. Developed GQSAR models reveled presence of lipophilic groups on fragment R6 will diminish the bio-activity while at R2 it will lead to increase in bioactivity of molecules. Additionally, minimum number of rotatable bonds at fragments R1 was fruitful for better FXa inhibition activity. The results of GQSAR models may lead to better understanding of design and development of novel FXa inhibitors.

🔖

Cite This Article

KUMBHAR, S. S., CHOUDHARİ, P. B., BHATIA, M. S. (2017). Investigation of fragment based quantitative regression on a series of substituted chromen-2-one derivatives as FXa inhibitors. Marmara Pharmaceutical Journal, Cilt: 21 - Sayı: 3, 620–630. https://ajindex.com/articles/283721

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bhatia MS, Ingale KB, Choudhari PB, Bhatia NM, Sawant RL. Application quantum and physico chemical molecular descriptors utilizing principal components to study mode of anticoagulant activity of pyridyl chromen-2-one derivatives. Bioorg Med Chem 2009; 17: 1654-62
  2. Bohm M, Sturzebecher J, Klebe GJ. Three-Dimensional quantitative structure−activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. Med Chem 1999; 42: 458-77
  3. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin. Circulation 2001; 103: 2994-3018
  4. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. P Natl Acad Sci USA 1989; 86: 3619-23
  5. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparinantithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91
  6. Walenga JM. An overview of the direct thrombin inhibitor argatroban. Pathophysiol Haemost Thromb 2002; 32: 9-14
  7. Riva N, Lip GY. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long term prevention of thromboembolic complications in patients with atrial fibrillation? Pol Arch Med Wewn 2012; 122: 45–53
  8. Hart RG, Pearce LA, Aquilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 857–67
  9. Perez A, Eraso L, Merli G. Implications of new anticoagulants in primary practice. Int J Clin Pract 2013; 67: 139–56
  10. Vílchez JA, Gallego P, Lip GY. Safety of new oral anticoagulant drugs: A perspective. Ther Adv Drug Saf 2014, 5: 8-20
  11. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516–21
  12. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of Atrial Fibrillation in the U.S. adult population. Am J Cardiol 2013; 112: 1142–7
  13. Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG, Kingma JH, Crijns HJ, Van Gelder IC,RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillat